Communication of the meeting of Transparency Council No. 19/2026 on 4 May 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 19/2026 on 4 May 2026 during which the following resolutions were adopted:

1. At its meeting on 4 May 2026, the Transparency Council adopted position No. 58/2026 on the evaluation of the drug Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalemia
2. At its meeting on 4 May 2026, the Transparency Council adopted position No. 59/2026 on the evaluation of the drug Kimmtrak (tebentafuspum) under the B.163.FM drug program. “Treatment of patients with choroidal melanoma (ICD-10: C69, C69.3, C69.4)”
3. At its meeting on 4 May 2026, the Transparency Council adopted position No. 60/2026 on the evaluation of the drug Voraxaze (glucarpidasum) under the drug program “Elimination of toxic plasma methotrexate concentrations in adults and children (ICD-10: T45.1)”
4. At its meeting on 4 May 2026, the Transparency Council adopted opinion No. 77/2026 on the inclusion of medicinal products containing the active ingredient enoxaparinum natricum in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics
5. At its meeting on 4 May 2026, the Transparency Council adopted opinion No. 78/2026 on the inclusion of medicinal products containing the active ingredient nadroparinum calcicum in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics

Transparency Council meeting protocol >>